Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-25-040396
Filing Date
2025-04-29
Accepted
2025-04-28 20:14:00
Documents
19
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ymab-20241231x10ka.htm   iXBRL 10-K/A 817451
2 EXHIBIT 10.44 ymab-20241231xex10d44.htm EX-10.44 27980
3 EXHIBIT 31.3 ymab-20241231xex31d3.htm EX-31.3 5117
4 EXHIBIT 31.4 ymab-20241231xex31d4.htm EX-31.4 5002
  Complete submission text file 0001104659-25-040396.txt   1275176

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ymab-20241231.xsd EX-101.SCH 4714
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ymab-20241231_def.xml EX-101.DEF 40782
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20241231_lab.xml EX-101.LAB 24281
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20241231_pre.xml EX-101.PRE 16408
21 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20241231x10ka_htm.xml XML 11858
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38650 | Film No.: 25882274
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)